Global Nanopharmaceutical Drugs Market

Global Nanopharmaceutical Drugs Market: Focus on Nanodrugs and its Application in Therapeutics, Competitive Landscape, and Country - Analysis and Forecast (2018-2026)

The global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026.

SKU: BH112A
Published Year: 2018
PLEASE SELECT A LICENSE TYPE
 
 
 

The pharmaceutical industry is focused on the most emerging branch in pharmaceutical sciences known as“ Pharmaceutical nanotechnology ”. The increasing prevalence of chronic diseases/disorder and development of the healthcare infrastructure are promoting the adoption of the novel medicine known as nanomedicine for better efficacy and improved patient outcome.

Nanomedicine works on same principle of nanotechnology, as the materials at nanoscale level possess unique characteristics as compared to macroscopic level. Nanomedicine has a multidisciplinary nature involving notions and techniques from biology, chemistry, and physics. Nanotechnology provides exceptional benefits when applied to medical devices and pharmaceuticals. Furthermore,  the patent cliff/expirations has the enabled the pharmaceutical companies to adopt new business strategies. Many blockbuster drugs are going off-patent but the introduction of  nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue  growth.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into ‘drug carrier type,’ ‘application,’ ‘distribution channel,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global nanopharmaceutical drugs market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global nanopharmaceutical drugs market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.

The answers to the following key questions can be derived from this report:

•    How did the Nanopharmaceutical Drugs market evolve, and what is its scope in the future?
•    What are the major market drivers, challenges, and opportunities in the global Nanopharmaceutical Drugs market?
•    What are the key developmental strategies that are implemented by the key players to sustain in this market?
•    How will the influencing factors affect the industry attractiveness?
•    How nanopharmaceutical Drugs is superior that conventional drugs?
•    How will the investments by public and private companies and government organizations affect the global nanopharmaceutical drugs market? 
•    What was the market size of the leading segments and sub-segments of the global nanopharmaceutical drugs market in 2017?
•    How will the industry evolve during the forecast period 2018-2026?
•    What will be the growth rate of the nanopharmaceutical drugs during the forecast period?
•    How will each segment of the global nanopharmaceutical drugs market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
•    Which drug carrier segment, application segment and distribution channel is expected to register the highest CAGR for the nanopharmaceutical drugs market?
•    What is the market size of nanopharmaceutical drugs in different countries of the world?
•    Which geographical region will contribute to the highest sales of nanopharmaceutical drugs?
•    Who are the key players in the nanopharmaceutical drugs market, and what are their contributions?

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

    Executive Summary
    1    Market Overview
          1.1    What are Nanopharmaceuticals?
          1.2    Historical Trends
          1.3    Comparative Analysis of Conventional Medicine and Nanomedicine
          1.4    Issues and Concerns in Nanotech Product Development and its Commercialization
          1.5    Impact of Market Drivers and Market Restraints
          1.6    Assumptions and Limitations for Market Size Calculations
          1.7    Global Nanopharmaceutical Drugs Market Scenario
 
    2    Market Dynamics
          2.1    Impact Analysis
          2.2    Market Drivers
                   2.2.1    Government Initiative
                   2.2.2    Nanopharmaceuticals: A Hope for Patent Expired Formulations
                   2.2.3    Increase in Number of Abbreviated New Drug Application (ANDA), Biologics License Application (BLA) Approvals: Closing the Gap for Generic Nanomedicines
                   2.2.4    Nanomedicine - Innovative Ways of Treating Challenging Conditions
          2.3    Market Restraints
                   2.3.1    Economic & Financial Barriers
                   2.3.2    Undefined Regulatory Approvals
          2.4    Market Opportunities
                   2.4.1    Pipeline Creating Market Opportunity
                   2.4.2    The Nanomedicine Market: Small Particles – Big Business
          2.5    Market Trends
                   2.5.1    Pfizer, Merck Focusing on Nanomedicine as Next Disruption in Pharma
                   2.5.2    Trends in Approval and Development
                   2.5.3    Publications Trend Scenario
 
    3    Competitive Insights
          3.1    Pipeline Analysis and Market Opportunity
          3.2    Product Launches and Approvals
 
    4    Industry Insights
          4.1    Introduction
          4.2    Patent Analysis
          4.3    Funding Scenario
          4.4    Regulatory Bodies
 
    5    Global Nanopharmaceutical Drug  Market (by Drug Carrier)
          5.1    Liposomes
          5.2    Polymer
          5.3    Nanocrystals
          5.4    Inorganic
          5.5    Protein
          5.6    Others
 
    6    Global Nanopharmaceutical Drugs Market (by Application)
          6.1    Oncology
          6.2    Neurology
          6.3    Anti-inflammatory/Immunology
          6.4    Anti-infective
          6.5    Cardiovascular/Physiology
          6.6    Others
 
    7    Global Nanopharmaceutical Drugs Market (by Distribution Channel)
          7.1    Hospital Pharmacies
          7.2    Retail Pharmacies
          7.3    Online Pharmacies
 
    8    Global Nanopharmaceutical Drugs Market (by Region)
          8.1    North America
                   8.1.1    The U.S.
                   8.1.2    Canada
          8.2    Europe
                   8.2.1    Germany
                   8.2.2    France
                   8.2.3    The U.K.
                   8.2.4    Spain
                   8.2.5    Italy
                   8.2.6    Rest-of-Europe
          8.3    Asia-Pacific
                   8.3.1    China
                   8.3.2    Japan
                   8.3.3    Rest-of-Asia-Pacific
          8.4    Rest-of-the-World
 
    9    Company Profiles
          Overview
          9.1    AbbVie Inc.
                   9.1.1    Company Overview
                   9.1.2    Role of Abbvie Inc. in Nanopharmaceuticals Drug Market
                   9.1.3    Financials
                   9.1.4    Key Insights about Financial Health of the Company
                   9.1.5    Global Presence
                   9.1.6    SWOT Analysis
          9.2    AMAG Pharmaceuticals
                   9.2.1    Company Overview
                   9.2.2    Role of AMAG Pharmaceutical in Global Nanopharmaceutical Drugs Market
                   9.2.3    Financials
                   9.2.4    Key Insights about Financial Health of the Company
                   9.2.5    Global Presence
                   9.2.6    SWOT Analysis
          9.3    Amgen Inc.
                   9.3.1    Company Overview
                   9.3.2    Role of Amgen Inc. in Nanopharmaceuticals Drug Market
                   9.3.3    Financials
                   9.3.4    Key Insights about Financial Health of the Company
                   9.3.5    Global Presence
                   9.3.6    SWOT Analysis
          9.4    Astellas Pharma Inc.
                   9.4.1    Company Overview
                   9.4.2    Role of Astellas Pharma Inc. in Global Nanopharmaceutical Drugs Market
                   9.4.3    Financials
                   9.4.4    Key Insights about Financial Health of the company
                   9.4.5    SWOT Analysis
          9.5    AstraZeneca PLC
                   9.5.1    Company Overview
                   9.5.2    Role of AstraZeneca PLC in Global Nanopharmaceutical Drugs Market
                   9.5.3    Financials
                   9.5.4    Key Insights about Financial Health of the company
                   9.5.5    Global Presence
                   9.5.6    SWOT Analysis
          9.6    CELGENE CORPORATION
                   9.6.1    Company Overview
                   9.6.2    Role of CELGENE CORPORATION in Global Nanopharmaceutical Drugs Market
                   9.6.3    Financials
                   9.6.4    Key Insights about Financial Health of the company
                   9.6.5    Global Presence
                   9.6.6    SWOT Analysis
          9.7    Gilead Sciences, Inc.
                   9.7.1    Company Overview
                   9.7.2    Role of Gilead Sciences, Inc in Global Nanopharmaceutical Drugs Market
                   9.7.3    Financials
                   9.7.4    Key Insights about Financial Health of the company
                   9.7.5    Global Presence
                   9.7.6    SWOT Analysis
          9.8    JOHNSON & JOHNSON
                   9.8.1    Company Overview
                   9.8.2    Role of Johnson & Johnson in Global Nanopharmaceutical Drugs Market
                   9.8.3    Financials
                   9.8.4    Key Insights about Financial Health of the company
                   9.8.5    Global Presence
                   9.8.6    SWOT Analysis
          9.9    Merck & Co., Inc.
                   9.9.1    Company Overview
                   9.9.2    Role of Merck & Co., Inc. in Nanopharmaceutical Drugs Market
                   9.9.3    Financials
                   9.9.4    Key Insights about Financial Health of the company
                   9.9.5    Global Presence
                   9.9.6    SWOT Analysis
         9.10   Novartis AG
                   9.10.1    Company Overview
                   9.10.2    Role of Novartis AG in Nanopharmaceutical Drugs Market
                   9.10.3    Financials
                   9.10.4    Key Insights about Financial Health of the company
                   9.10.5    Global Presence
                   9.10.6    SWOT Analysis
         9.11   Pfizer, Inc.
                   9.11.1    Company Overview
                   9.11.2    Role of Pfizer, Inc. in the Pharmaceutical Drug Market
                   9.11.3    Financials
                   9.11.4    Key Insights on the Financial Health of the Company
                   9.11.5    Global Presence
                   9.11.6    SWOT Analysis
         9.12   Hoffmann-La Roche AG
                   9.12.1    Company Overview
                   9.12.2    Role of F. Hoffmann-La Roche AG in the Nanopharmaceutical Drugs Market
                   9.12.3    Financials
                   9.12.4    Key Insights about Financial Health of the company
                   9.12.5    Global Presence
                   9.12.6    SWOT Analysis
         9.13   Sanofi S.A
                   9.13.1    Company Overview
                   9.13.2    Role of Sanofi S.A in Global Nanopharmaceutical Drugs Market
                   9.13.3    Financials
                   9.13.4    Key Insights about Financial Health of the company
                   9.13.5    Global Presence
                   9.13.6    SWOT Analysis
         9.14   Shire Plc.
                   9.14.1    Company Overview
                   9.14.2    Role of Shire plc. in Global Nanopharmaceutical Drugs Market
                   9.14.3    Financials
                   9.14.4    Key Insights about Financial Health of the company
                   9.14.5    Global Presence
                   9.14.6    SWOT Analysis
         9.15   Teva Pharmaceuticals Industries Limited
                    9.15.1    Company Overview
                    9.15.2    Teva Pharmaceuticals Industries Limited in Nanopharmaceutical Drugs Market
                    9.15.3    Financials
                    9.15.4    Key Insights about Financial Health of the company
                    9.15.5    Global Presence
                    9.15.6    SWOT Analysis
 
    10    Research Scope and Methodology
            10.1    Report Scope
            10.2    Global Nanopharmaceutical Drugs Market: Research Methodology
 

List of Tables

Table 1    Cancer Incidences (by Region), 2015
Table 2    Characterization Tools and Methods for Nanoparticles
Table 1.1    Various Characteristics and Brief Applications of Nanosystems
Table 1.2    Conventional Medicine vs. Nanomedicine
Table 2.1    Impact Analysis
Table 3.1    Drug Candidates in Different Phase of Development
Table 3.2    Nanopharmaceutical Drug Approvals
Table 4.1    Criterion for Patentability
Table 4.2    Selected Case Law Pertaining to Nanotechnology
Table 4.3    List of Regulatory Bodies across the World
Table 5.1    List of Liposome NPs
Table 5.2    List of Polymer NPs
Table 5.3    List of Nanocrystal NPs
Table 5.4    List of Inorganic NPs
Table 5.5    List of Protein NPs
Table 6.1    Currently Approved Nanomedicines in the Clinic (Cancer)
Table 8.1    North America Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026, $B
Table 8.2    North America Nanopharmaceutical Drugs Market (by Application), 2017-2026, $Billion
Table 8.3    Europe Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026
Table 8.4    Europe Nanopharmaceutical Drugs Market (by Application), 2017-2026
Table 8.5    Asia-Pacific Nanopharmaceutical Drugs Market(by Drug Carrier Type), 2017-2026
Table 8.6    Asia-Pacific Nanopharmaceutical Drugs Market, by Application, 2017-2026

List of Figures

Figure 1    Evolution of Nanomedicine
Figure 2    Global Nanopharmaceutical Drugs Market Share (by Drug Carrier Type), 2017
Figure 3    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2018 - 2026
Figure 4    Global Nanopharmaceutical Drugs Market (by Application), 2018 - 2026
Figure 5    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2018 - 2026
Figure 6    Global Nanopharmaceutical Drug Market, (by Region), 2017, 2021, and 2026
Figure 7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 8    Global Nanopharmaceutical Drugs Market, 2017-2026, Y-o-Y
Figure 9    Nanomedicine Market: Impacting Factors
Figure 10    Global Nanopharmaceutical Drugs Market, Absolute Dollar Opportunity, Billion (by Region)
Figure 11    Global Nanopharmaceutical Drugs Market, Market Attractiveness (By Application)
Figure 1.1    Different Types of Biomarkers in Nanopharmaceutical Drug
Figure 1.2    Drug Particle Prepared in the Nanoscale Depends on Four Aspects of Nanopharmaceutical Lifestyle
Figure 1.3    Era of Nanodrug Delivery in Cancer
Figure 1.4    Introduction to Nanomedicine: Years of Commercialization
Figure 1.5    Concerns in Nanotech Product Development and its Commercialization
Figure 1.6    Impact of Market Drivers and Market Restraints
Figure 1.7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 2.1    Market Dynamics
Figure 2.2    NNI Budget (by Agency), 2017–2019 (Proposed)
Figure 2.3    Number of ANDA Approvals, 2017
Figure 2.4    Nanotechnology Business
Figure 2.5    Pipeline Drugs: Clinical Opportunity
Figure 2.6    Pipeline Drugs: On Map
Figure 2.7    Nano based Drug Delivery Patent Filing, (By Region), 2015
Figure 2.8    Nanoparticles in Approved and Investigational Drugs, 2017
Figure 3.1    Market Potential, Drug Peak Sale ($Billion)
Figure 4.1    Industry Insights
Figure 4.2    Patent Expiration (By Drug Carrier Type), 2016
Figure 5.1    Types of  Nanocarriers
Figure 5.2    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017 and 2026
Figure 5.3    Global Nanopharmaceutical Drugs Market (by Liposome Drug Carrier), 2017-2026
Figure 5.4    Global Nanopharmaceutical Drugs Market (by Polymer NP), 2017-2026
Figure 5.5    Global Nanopharmaceutical Drugs Market (by Nanocrystal Drug Carrier), 2017-2026
Figure 5.6    Global Nanopharmaceutical Drugs Market (by Inorganic), 2017-2026
Figure 5.7    Global Nanopharmaceutical Drugs Market (by Protein Drug Carrier), 2017-2026
Figure 5.8    Global Nanopharmaceutical Drugs Market (by Other Drug Carrier), 2017-2026
Figure 6.1    Global Nanopharmaceutical Drugs Market (by Application)
Figure 6.2    Global Nanopharmaceutical Drugs Market (by Products), 2017-2026
Figure 6.3    Global Nanopharmaceutical Drugs Market (by Oncology), 2017-2026
Figure 6.4    Nanomedicine in Neurology
Figure 6.5    Global Nanopharmaceutical Drugs Market (by Neurology), 2017-2026
Figure 6.6    Global Nanopharmaceutical Drugs Market (by Anti-inflammatory/Immunology), 2017-2026
Figure 6.7    Global Nanopharmaceutical Drugs Market (by Anti-infectives), 2017-2026
Figure 6.8    Global Nanopharmaceutical Drugs Market (by Cardiovascular and Physiology), 2017-2026
Figure 6.9    Global Nanopharmaceutical Drugs Market (by Other Application Areas), 2017-2026
Figure 7.1    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2017-2026
Figure 7.2    Global Nanopharmaceutical Drugs Market (by Hospital Pharmacy), 2017-2026
Figure 7.3    Global Nanopharmaceutical Drugs Market (by Retail and Drug Store), 2017-2026
Figure 7.4    Global Nanopharmaceutical Drugs Market (by Online Pharmacy), 2017-2026
Figure 8.1    Global Nanopharmaceutical Drugs Market Scenario, (CAGR), 2018-2026, (Market Value), (2017)
Figure 8.2    Global Nanopharmaceutical Drugs Market (by Region), 2017-2026
Figure 8.3    Global Nanopharmaceutical Drugs Market Share (by Region), 2017 and 2026
Figure 8.4    North America Nanopharmaceutical Drugs Market, (2017-2026)
Figure 8.5    North America Market Dynamics
Figure 8.6    North America Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.7    The U.S Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.8    Canada Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.9    Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.10    Europe Market Dynamics
Figure 8.11    Europe Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.12    Germany Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.13    France Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.14    The U.K. Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.15    Spain Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.16    Italy Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.17    Rest-of-Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.18    Asia-Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.19    Asia-Pacific Market Dynamics
Figure 8.20    Asia Pacific Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.21    China Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.22    Japan Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.23    Rest-of-Asia Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.24    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Drug Carrier), 2017-2026
Figure 8.25    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Application), 2017-2026
Figure 9.1    Abbvie Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.2    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.3    Abbvie Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.4    Abbvie Inc.: R&D Expense, 2015-2017
Figure 9.5    Abbvie Inc.: Revenue Forecast, 2015-2020
Figure 9.6    Abbvie Inc.: Global Presence
Figure 9.7    Abbvie Inc.: SWOT Analysis
Figure 9.8    AMAG Pharmaceuticals: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.9    AMAG Pharmaceuticals: Overall Financials, 2015-2017
Figure 9.10    AMAG Pharmaceuticals: Revenue (by Business Segment), 2015-2017
Figure 9.11    AMAG Pharmaceuticals: R&D Expense, 2015-2017
Figure 9.12    AMAG Pharmaceuticals: Revenue Forecast, 2015-2020
Figure 9.13    AMAG Pharmaceuticals: Global Presence
Figure 9.14    AMAG Pharmaceuticals: SWOT Analysis
Figure 9.15    Amgen, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.16    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.17    Amgen Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.18    Amgen, Inc.: R&D Expense, 2015-2017
Figure 9.19    Amgen, Inc.: Revenue Forecast, 2015-2020
Figure 9.20    Amgen Inc.: Global Presence
Figure 9.21    Amgen, Inc.: SWOT Analysis
Figure 9.22    Astellas Pharma Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.23    Astellas Pharma Inc: Overall Financials, 2015-2017
Figure 9.24    Astellas Pharma Inc: Revenue (by Business Segment), 2016-2017
Figure 9.25    Astellas Pharma Inc.: Revenue (by Region), 2016-2017
Figure 9.26    Astellas Pharma Inc: R&D Expense, 2015-2017
Figure 9.27    AstraZeneca PLC: Revenue Forecast, 2015-2020
Figure 9.28    Astella Pharma Inc, SWOT Analysis
Figure 9.29    AstraZeneca PLC: Overall Financials, 2015-2017
Figure 9.30    AstraZeneca PLC: Revenue (by Region), 2015-2017
Figure 9.31    AstraZeneca PLC: R&D Expense, 2015-2017
Figure 9.32    AstraZeneca PLC: Global Presence
Figure 9.33    AstraZeneca PLC: SWOT Analysis
Figure 9.34    CELGENE CORPORATION: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.35    CELGENE CORPORATION: Overall Financials, 2015-2017
Figure 9.36    CELGENE CORPORATION: Revenue (by Region), 2015-2017
Figure 9.37    CELGENE CORPORATION: R&D Expense, 2015-2017
Figure 9.38    CELGENE CORPORATION: Revenue Forecast, 2015-2020
Figure 9.39    CELGENE CORPORATION: Global Presence
Figure 9.40    CELGENE CORPORATION: SWOT Analysis
Figure 9.41    Gilead Sciences, Inc: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.42    Gilead Sciences, Inc: Overall Financials, 2015-2017
Figure 9.43    Gilead Sciences, Inc: Revenue (by Region), 2015-2017
Figure 9.44    Gilead Sciences, Inc: R&D Expense, 2015-2017
Figure 9.45    Gilead Sciences, Inc: Revenue Forecast, 2015-2020
Figure 9.46    Gilead Sciences, Inc: Global Presence
Figure 9.47    Gilead Sciences, Inc: SWOT Analysis
Figure 9.48    Johnson & Johnson: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.49    Johnson & Johnson: Overall Financials, 2015-2017
Figure 9.50    Johnson & Johnson: Revenue (by Business Segment), 2015-2017
Figure 9.51    Johnson & Johnson: Revenue (by Region), 2015-2017
Figure 9.52    Johnson & Johnson: R&D Expense, 2015-2017
Figure 9.53    Johnson & Johnson: Revenue Forecast, 2015-2020
Figure 9.54    Johnson & Johnson: Global Presence
Figure 9.55    Johnson & Johnson: SWOT Analysis
Figure 9.56    Merck & Co., Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.57    Merck & Co., Inc.: Overall Financials, 2015-2017
Figure 9.58    Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
Figure 9.59    Merck & Co., Inc.: Revenue (by Region), 2015-2017
Figure 9.60    Merck & Co., Inc.: R&D Expense, 2015-2017
Figure 9.61    Merck & Co., Inc.: Revenue Forecast, 2015-2020
Figure 9.62    Merck & Co., Inc.: Global Presence
Figure 9.63    Merck & Co., Inc.: SWOT Analysis
Figure 9.64    Novartis AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.65    Novartis AG: Overall Financials, 2015-2017
Figure 9.66    Novartis AG: Revenue (by Business Segment), 2015-2017
Figure 9.67    Novartis AG: Revenue (by Region), 2015-2017
Figure 9.68    Novartis AG: R&D Expense, 2015-2017
Figure 9.69    Novartis AG: Revenue Forecast, 2015-2020
Figure 9.70    Novartis AG: Global Presence
Figure 9.71    Novartis AG: SWOT Analysis
Figure 9.72    Pfizer, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.73    Pfizer, Inc.: Overall Financials, 2015-2017
Figure 9.74    Pfizer, Inc.: Revenue (by Business Segment), 2015, 2016 and 2017
Figure 9.75    Pfizer, Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.76    Pfizer, Inc.: R&D Expense, 2015-2017
Figure 9.77    Pfizer, Inc.: Revenue Forecast, 2015-2020
Figure 9.78    Pfizer, Inc.: Global Presence
Figure 9.79    Pfizer, Inc.: SWOT Analysis
Figure 9.80    F. Hoffmann-La Roche AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.81    F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 9.82    F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure 9.83    F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 9.84    F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure 9.85    F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 9.86    F. Hoffmann-La Roche AG: Global Presence
Figure 9.87    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 9.88    Sanofi S.A.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.89    Sanofi S.A: Overall Financials, 2015-2017
Figure 9.90    Sanofi S.A: Revenue (by Business Segment), 2015-2017
Figure 9.91    Sanofi S.A: Revenue (by Region), 2015-2017
Figure 9.92    Sanofi S.A: R&D Expense, 2015-2017
Figure 9.93    Sanofi S.A: Revenue Forecast, 2015-2020
Figure 9.94    Sanofi S.A: Global Presence
Figure 9.95    Sanofi S.A: SWOT Analysis
Figure 9.96    Shire plc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.97    Shire plc.: Overall Financials, 2015-2017
Figure 9.98    Shire PLC: Revenue (by Business Segment), 2015-2017
Figure 9.99    Shire PLC: R&D Expense, 2015-2017
Figure 9.100    Shire PLC: Revenue Forecast, 2015-2020
Figure 9.101    Shire PLC: Global Presence
Figure 9.102    Shire PLC: SWOT Analysis
Figure 9.103    Teva Pharmaceuticals Industries Limited: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.104    Teva Pharmaceuticals Industries Limited: Overall Financials, 2015-2017
Figure 9.105    Teva Pharmaceuticals Industries Limited: Revenue (by Business Segment), 2015-2017
Figure 9.106    Teva Pharmaceuticals Industries Limited: Revenue (by Region), 2015-2017
Figure 9.107    Teva Pharmaceuticals Industries Limited: R&D Expense, 2015-2017
Figure 9.108    Teva Pharmaceuticals Industries Limited: Revenue Forecast, 2015-2020
Figure 9.109    Teva Pharmaceuticals Industries Limited: Global Presence
Figure 9.110    Teva Pharmaceuticals Industries Limited: SWOT Analysis
Figure 10.1    Global Nanopharmaceutical Drugs Market Scope
Figure 10.2    Global Nanopharmaceutical Drugs Market: Research Methodology
Figure 10.3    Primary Research
Figure 10.4    Secondary Research
Figure 10.5    Data Triangulation
Figure 10.6    Top-down Approach (Segment-wise Analysis)
Figure 10.7    Bottom-up Approach (Segment-wise Analysis)
Figure 10.8    Assumptions and Limitations
Figure 10.9    Considered Factors for Data Prediction and Modelling

Big pharma companies rely on blockbuster drugs for revenue generation. The patent protection allows the pharma company to sell the drugs at high profit margin, for example the Pfizer’s drug known as Lipitor, accounts for about $13 bn of Pfizer's revenues. Many blockbuster drugs are going off patent, drug manufacturers are facing challenges to develop novel research and development strategies, involving miniaturization through various techniques including nanotechnology.

The introduction of nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue growth.

The nanopharmaceuticals have broach range of application and are used in imaging, diagnostics and therapeutics and possess full potential to dominate the pharmaceutical market. The introduction of nanomedicine will alter the landscape of medicine and will drastically improve a patient's quality of life and reduce healthcare costs.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into ‘drug carrier type,’ ‘application,’ ‘distribution channel,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market. The global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026.

The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. are the key drivers for the growth of the nanopharmaceutical drugs market.

Moreover, among different therapeutic areas, the oncology therapeutic area  dominated the global nanopharmaceutical drugs market in 2017. Nanoparticles offer an opportunity to introduce overall shift in cancer research. Many drug candidates are under clinical investigation and have the potential to be introduced in the market. Ideal nanomedicines should follow the regulatory pathway of approval and should have a modular design that can be easily scaled up for cGMP manufacturing and stored for a long time prior to use in patients. The Nanotechnology Characterization Laboratory and FDA works in collaboration to advance and review nanomedicine platform.

On the basis of regions, the global nanopharmaceutical drugs market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global nanopharmaceutical drugs market and contributed 51.78% in terms of revenue respectively to the global market in 2017. However, Europe and Asia-Pacific is expected to grow at a significant CAGR  between 5% to 7% in terms of revenue respectively, during the forecast period.

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields
 

The pharmaceutical industry is focused on the most emerging branch in pharmaceutical sciences known as“ Pharmaceutical nanotechnology ”. The increasing prevalence of chronic diseases/disorder and development of the healthcare infrastructure are promoting the adoption of the novel medicine known as nanomedicine for better efficacy and improved patient outcome.

Nanomedicine works on same principle of nanotechnology, as the materials at nanoscale level possess unique characteristics as compared to macroscopic level. Nanomedicine has a multidisciplinary nature involving notions and techniques from biology, chemistry, and physics. Nanotechnology provides exceptional benefits when applied to medical devices and pharmaceuticals. Furthermore,  the patent cliff/expirations has the enabled the pharmaceutical companies to adopt new business strategies. Many blockbuster drugs are going off-patent but the introduction of  nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue  growth.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into ‘drug carrier type,’ ‘application,’ ‘distribution channel,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global nanopharmaceutical drugs market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global nanopharmaceutical drugs market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.

The answers to the following key questions can be derived from this report:

•    How did the Nanopharmaceutical Drugs market evolve, and what is its scope in the future?
•    What are the major market drivers, challenges, and opportunities in the global Nanopharmaceutical Drugs market?
•    What are the key developmental strategies that are implemented by the key players to sustain in this market?
•    How will the influencing factors affect the industry attractiveness?
•    How nanopharmaceutical Drugs is superior that conventional drugs?
•    How will the investments by public and private companies and government organizations affect the global nanopharmaceutical drugs market? 
•    What was the market size of the leading segments and sub-segments of the global nanopharmaceutical drugs market in 2017?
•    How will the industry evolve during the forecast period 2018-2026?
•    What will be the growth rate of the nanopharmaceutical drugs during the forecast period?
•    How will each segment of the global nanopharmaceutical drugs market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?
•    Which drug carrier segment, application segment and distribution channel is expected to register the highest CAGR for the nanopharmaceutical drugs market?
•    What is the market size of nanopharmaceutical drugs in different countries of the world?
•    Which geographical region will contribute to the highest sales of nanopharmaceutical drugs?
•    Who are the key players in the nanopharmaceutical drugs market, and what are their contributions?

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

    Executive Summary
    1    Market Overview
          1.1    What are Nanopharmaceuticals?
          1.2    Historical Trends
          1.3    Comparative Analysis of Conventional Medicine and Nanomedicine
          1.4    Issues and Concerns in Nanotech Product Development and its Commercialization
          1.5    Impact of Market Drivers and Market Restraints
          1.6    Assumptions and Limitations for Market Size Calculations
          1.7    Global Nanopharmaceutical Drugs Market Scenario
 
    2    Market Dynamics
          2.1    Impact Analysis
          2.2    Market Drivers
                   2.2.1    Government Initiative
                   2.2.2    Nanopharmaceuticals: A Hope for Patent Expired Formulations
                   2.2.3    Increase in Number of Abbreviated New Drug Application (ANDA), Biologics License Application (BLA) Approvals: Closing the Gap for Generic Nanomedicines
                   2.2.4    Nanomedicine - Innovative Ways of Treating Challenging Conditions
          2.3    Market Restraints
                   2.3.1    Economic & Financial Barriers
                   2.3.2    Undefined Regulatory Approvals
          2.4    Market Opportunities
                   2.4.1    Pipeline Creating Market Opportunity
                   2.4.2    The Nanomedicine Market: Small Particles – Big Business
          2.5    Market Trends
                   2.5.1    Pfizer, Merck Focusing on Nanomedicine as Next Disruption in Pharma
                   2.5.2    Trends in Approval and Development
                   2.5.3    Publications Trend Scenario
 
    3    Competitive Insights
          3.1    Pipeline Analysis and Market Opportunity
          3.2    Product Launches and Approvals
 
    4    Industry Insights
          4.1    Introduction
          4.2    Patent Analysis
          4.3    Funding Scenario
          4.4    Regulatory Bodies
 
    5    Global Nanopharmaceutical Drug  Market (by Drug Carrier)
          5.1    Liposomes
          5.2    Polymer
          5.3    Nanocrystals
          5.4    Inorganic
          5.5    Protein
          5.6    Others
 
    6    Global Nanopharmaceutical Drugs Market (by Application)
          6.1    Oncology
          6.2    Neurology
          6.3    Anti-inflammatory/Immunology
          6.4    Anti-infective
          6.5    Cardiovascular/Physiology
          6.6    Others
 
    7    Global Nanopharmaceutical Drugs Market (by Distribution Channel)
          7.1    Hospital Pharmacies
          7.2    Retail Pharmacies
          7.3    Online Pharmacies
 
    8    Global Nanopharmaceutical Drugs Market (by Region)
          8.1    North America
                   8.1.1    The U.S.
                   8.1.2    Canada
          8.2    Europe
                   8.2.1    Germany
                   8.2.2    France
                   8.2.3    The U.K.
                   8.2.4    Spain
                   8.2.5    Italy
                   8.2.6    Rest-of-Europe
          8.3    Asia-Pacific
                   8.3.1    China
                   8.3.2    Japan
                   8.3.3    Rest-of-Asia-Pacific
          8.4    Rest-of-the-World
 
    9    Company Profiles
          Overview
          9.1    AbbVie Inc.
                   9.1.1    Company Overview
                   9.1.2    Role of Abbvie Inc. in Nanopharmaceuticals Drug Market
                   9.1.3    Financials
                   9.1.4    Key Insights about Financial Health of the Company
                   9.1.5    Global Presence
                   9.1.6    SWOT Analysis
          9.2    AMAG Pharmaceuticals
                   9.2.1    Company Overview
                   9.2.2    Role of AMAG Pharmaceutical in Global Nanopharmaceutical Drugs Market
                   9.2.3    Financials
                   9.2.4    Key Insights about Financial Health of the Company
                   9.2.5    Global Presence
                   9.2.6    SWOT Analysis
          9.3    Amgen Inc.
                   9.3.1    Company Overview
                   9.3.2    Role of Amgen Inc. in Nanopharmaceuticals Drug Market
                   9.3.3    Financials
                   9.3.4    Key Insights about Financial Health of the Company
                   9.3.5    Global Presence
                   9.3.6    SWOT Analysis
          9.4    Astellas Pharma Inc.
                   9.4.1    Company Overview
                   9.4.2    Role of Astellas Pharma Inc. in Global Nanopharmaceutical Drugs Market
                   9.4.3    Financials
                   9.4.4    Key Insights about Financial Health of the company
                   9.4.5    SWOT Analysis
          9.5    AstraZeneca PLC
                   9.5.1    Company Overview
                   9.5.2    Role of AstraZeneca PLC in Global Nanopharmaceutical Drugs Market
                   9.5.3    Financials
                   9.5.4    Key Insights about Financial Health of the company
                   9.5.5    Global Presence
                   9.5.6    SWOT Analysis
          9.6    CELGENE CORPORATION
                   9.6.1    Company Overview
                   9.6.2    Role of CELGENE CORPORATION in Global Nanopharmaceutical Drugs Market
                   9.6.3    Financials
                   9.6.4    Key Insights about Financial Health of the company
                   9.6.5    Global Presence
                   9.6.6    SWOT Analysis
          9.7    Gilead Sciences, Inc.
                   9.7.1    Company Overview
                   9.7.2    Role of Gilead Sciences, Inc in Global Nanopharmaceutical Drugs Market
                   9.7.3    Financials
                   9.7.4    Key Insights about Financial Health of the company
                   9.7.5    Global Presence
                   9.7.6    SWOT Analysis
          9.8    JOHNSON & JOHNSON
                   9.8.1    Company Overview
                   9.8.2    Role of Johnson & Johnson in Global Nanopharmaceutical Drugs Market
                   9.8.3    Financials
                   9.8.4    Key Insights about Financial Health of the company
                   9.8.5    Global Presence
                   9.8.6    SWOT Analysis
          9.9    Merck & Co., Inc.
                   9.9.1    Company Overview
                   9.9.2    Role of Merck & Co., Inc. in Nanopharmaceutical Drugs Market
                   9.9.3    Financials
                   9.9.4    Key Insights about Financial Health of the company
                   9.9.5    Global Presence
                   9.9.6    SWOT Analysis
         9.10   Novartis AG
                   9.10.1    Company Overview
                   9.10.2    Role of Novartis AG in Nanopharmaceutical Drugs Market
                   9.10.3    Financials
                   9.10.4    Key Insights about Financial Health of the company
                   9.10.5    Global Presence
                   9.10.6    SWOT Analysis
         9.11   Pfizer, Inc.
                   9.11.1    Company Overview
                   9.11.2    Role of Pfizer, Inc. in the Pharmaceutical Drug Market
                   9.11.3    Financials
                   9.11.4    Key Insights on the Financial Health of the Company
                   9.11.5    Global Presence
                   9.11.6    SWOT Analysis
         9.12   Hoffmann-La Roche AG
                   9.12.1    Company Overview
                   9.12.2    Role of F. Hoffmann-La Roche AG in the Nanopharmaceutical Drugs Market
                   9.12.3    Financials
                   9.12.4    Key Insights about Financial Health of the company
                   9.12.5    Global Presence
                   9.12.6    SWOT Analysis
         9.13   Sanofi S.A
                   9.13.1    Company Overview
                   9.13.2    Role of Sanofi S.A in Global Nanopharmaceutical Drugs Market
                   9.13.3    Financials
                   9.13.4    Key Insights about Financial Health of the company
                   9.13.5    Global Presence
                   9.13.6    SWOT Analysis
         9.14   Shire Plc.
                   9.14.1    Company Overview
                   9.14.2    Role of Shire plc. in Global Nanopharmaceutical Drugs Market
                   9.14.3    Financials
                   9.14.4    Key Insights about Financial Health of the company
                   9.14.5    Global Presence
                   9.14.6    SWOT Analysis
         9.15   Teva Pharmaceuticals Industries Limited
                    9.15.1    Company Overview
                    9.15.2    Teva Pharmaceuticals Industries Limited in Nanopharmaceutical Drugs Market
                    9.15.3    Financials
                    9.15.4    Key Insights about Financial Health of the company
                    9.15.5    Global Presence
                    9.15.6    SWOT Analysis
 
    10    Research Scope and Methodology
            10.1    Report Scope
            10.2    Global Nanopharmaceutical Drugs Market: Research Methodology
 

List of Tables

Table 1    Cancer Incidences (by Region), 2015
Table 2    Characterization Tools and Methods for Nanoparticles
Table 1.1    Various Characteristics and Brief Applications of Nanosystems
Table 1.2    Conventional Medicine vs. Nanomedicine
Table 2.1    Impact Analysis
Table 3.1    Drug Candidates in Different Phase of Development
Table 3.2    Nanopharmaceutical Drug Approvals
Table 4.1    Criterion for Patentability
Table 4.2    Selected Case Law Pertaining to Nanotechnology
Table 4.3    List of Regulatory Bodies across the World
Table 5.1    List of Liposome NPs
Table 5.2    List of Polymer NPs
Table 5.3    List of Nanocrystal NPs
Table 5.4    List of Inorganic NPs
Table 5.5    List of Protein NPs
Table 6.1    Currently Approved Nanomedicines in the Clinic (Cancer)
Table 8.1    North America Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026, $B
Table 8.2    North America Nanopharmaceutical Drugs Market (by Application), 2017-2026, $Billion
Table 8.3    Europe Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017-2026
Table 8.4    Europe Nanopharmaceutical Drugs Market (by Application), 2017-2026
Table 8.5    Asia-Pacific Nanopharmaceutical Drugs Market(by Drug Carrier Type), 2017-2026
Table 8.6    Asia-Pacific Nanopharmaceutical Drugs Market, by Application, 2017-2026

List of Figures

Figure 1    Evolution of Nanomedicine
Figure 2    Global Nanopharmaceutical Drugs Market Share (by Drug Carrier Type), 2017
Figure 3    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2018 - 2026
Figure 4    Global Nanopharmaceutical Drugs Market (by Application), 2018 - 2026
Figure 5    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2018 - 2026
Figure 6    Global Nanopharmaceutical Drug Market, (by Region), 2017, 2021, and 2026
Figure 7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 8    Global Nanopharmaceutical Drugs Market, 2017-2026, Y-o-Y
Figure 9    Nanomedicine Market: Impacting Factors
Figure 10    Global Nanopharmaceutical Drugs Market, Absolute Dollar Opportunity, Billion (by Region)
Figure 11    Global Nanopharmaceutical Drugs Market, Market Attractiveness (By Application)
Figure 1.1    Different Types of Biomarkers in Nanopharmaceutical Drug
Figure 1.2    Drug Particle Prepared in the Nanoscale Depends on Four Aspects of Nanopharmaceutical Lifestyle
Figure 1.3    Era of Nanodrug Delivery in Cancer
Figure 1.4    Introduction to Nanomedicine: Years of Commercialization
Figure 1.5    Concerns in Nanotech Product Development and its Commercialization
Figure 1.6    Impact of Market Drivers and Market Restraints
Figure 1.7    Global Nanopharmaceutical Drugs Market, 2017-2026
Figure 2.1    Market Dynamics
Figure 2.2    NNI Budget (by Agency), 2017–2019 (Proposed)
Figure 2.3    Number of ANDA Approvals, 2017
Figure 2.4    Nanotechnology Business
Figure 2.5    Pipeline Drugs: Clinical Opportunity
Figure 2.6    Pipeline Drugs: On Map
Figure 2.7    Nano based Drug Delivery Patent Filing, (By Region), 2015
Figure 2.8    Nanoparticles in Approved and Investigational Drugs, 2017
Figure 3.1    Market Potential, Drug Peak Sale ($Billion)
Figure 4.1    Industry Insights
Figure 4.2    Patent Expiration (By Drug Carrier Type), 2016
Figure 5.1    Types of  Nanocarriers
Figure 5.2    Global Nanopharmaceutical Drugs Market (by Drug Carrier Type), 2017 and 2026
Figure 5.3    Global Nanopharmaceutical Drugs Market (by Liposome Drug Carrier), 2017-2026
Figure 5.4    Global Nanopharmaceutical Drugs Market (by Polymer NP), 2017-2026
Figure 5.5    Global Nanopharmaceutical Drugs Market (by Nanocrystal Drug Carrier), 2017-2026
Figure 5.6    Global Nanopharmaceutical Drugs Market (by Inorganic), 2017-2026
Figure 5.7    Global Nanopharmaceutical Drugs Market (by Protein Drug Carrier), 2017-2026
Figure 5.8    Global Nanopharmaceutical Drugs Market (by Other Drug Carrier), 2017-2026
Figure 6.1    Global Nanopharmaceutical Drugs Market (by Application)
Figure 6.2    Global Nanopharmaceutical Drugs Market (by Products), 2017-2026
Figure 6.3    Global Nanopharmaceutical Drugs Market (by Oncology), 2017-2026
Figure 6.4    Nanomedicine in Neurology
Figure 6.5    Global Nanopharmaceutical Drugs Market (by Neurology), 2017-2026
Figure 6.6    Global Nanopharmaceutical Drugs Market (by Anti-inflammatory/Immunology), 2017-2026
Figure 6.7    Global Nanopharmaceutical Drugs Market (by Anti-infectives), 2017-2026
Figure 6.8    Global Nanopharmaceutical Drugs Market (by Cardiovascular and Physiology), 2017-2026
Figure 6.9    Global Nanopharmaceutical Drugs Market (by Other Application Areas), 2017-2026
Figure 7.1    Global Nanopharmaceutical Drugs Market (by Distribution Channel), 2017-2026
Figure 7.2    Global Nanopharmaceutical Drugs Market (by Hospital Pharmacy), 2017-2026
Figure 7.3    Global Nanopharmaceutical Drugs Market (by Retail and Drug Store), 2017-2026
Figure 7.4    Global Nanopharmaceutical Drugs Market (by Online Pharmacy), 2017-2026
Figure 8.1    Global Nanopharmaceutical Drugs Market Scenario, (CAGR), 2018-2026, (Market Value), (2017)
Figure 8.2    Global Nanopharmaceutical Drugs Market (by Region), 2017-2026
Figure 8.3    Global Nanopharmaceutical Drugs Market Share (by Region), 2017 and 2026
Figure 8.4    North America Nanopharmaceutical Drugs Market, (2017-2026)
Figure 8.5    North America Market Dynamics
Figure 8.6    North America Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.7    The U.S Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.8    Canada Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.9    Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.10    Europe Market Dynamics
Figure 8.11    Europe Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.12    Germany Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.13    France Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.14    The U.K. Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.15    Spain Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.16    Italy Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.17    Rest-of-Europe Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.18    Asia-Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.19    Asia-Pacific Market Dynamics
Figure 8.20    Asia Pacific Nanopharmaceutical Drugs Market (by Country), 2017-2026
Figure 8.21    China Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.22    Japan Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.23    Rest-of-Asia Pacific Nanopharmaceutical Drugs Market, 2017-2026
Figure 8.24    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Drug Carrier), 2017-2026
Figure 8.25    Rest-of-the-World Nanopharmaceutical Drugs Market, (by Application), 2017-2026
Figure 9.1    Abbvie Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.2    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.3    Abbvie Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.4    Abbvie Inc.: R&D Expense, 2015-2017
Figure 9.5    Abbvie Inc.: Revenue Forecast, 2015-2020
Figure 9.6    Abbvie Inc.: Global Presence
Figure 9.7    Abbvie Inc.: SWOT Analysis
Figure 9.8    AMAG Pharmaceuticals: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.9    AMAG Pharmaceuticals: Overall Financials, 2015-2017
Figure 9.10    AMAG Pharmaceuticals: Revenue (by Business Segment), 2015-2017
Figure 9.11    AMAG Pharmaceuticals: R&D Expense, 2015-2017
Figure 9.12    AMAG Pharmaceuticals: Revenue Forecast, 2015-2020
Figure 9.13    AMAG Pharmaceuticals: Global Presence
Figure 9.14    AMAG Pharmaceuticals: SWOT Analysis
Figure 9.15    Amgen, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.16    Abbvie Inc.: Overall Financials, 2015-2017
Figure 9.17    Amgen Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.18    Amgen, Inc.: R&D Expense, 2015-2017
Figure 9.19    Amgen, Inc.: Revenue Forecast, 2015-2020
Figure 9.20    Amgen Inc.: Global Presence
Figure 9.21    Amgen, Inc.: SWOT Analysis
Figure 9.22    Astellas Pharma Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.23    Astellas Pharma Inc: Overall Financials, 2015-2017
Figure 9.24    Astellas Pharma Inc: Revenue (by Business Segment), 2016-2017
Figure 9.25    Astellas Pharma Inc.: Revenue (by Region), 2016-2017
Figure 9.26    Astellas Pharma Inc: R&D Expense, 2015-2017
Figure 9.27    AstraZeneca PLC: Revenue Forecast, 2015-2020
Figure 9.28    Astella Pharma Inc, SWOT Analysis
Figure 9.29    AstraZeneca PLC: Overall Financials, 2015-2017
Figure 9.30    AstraZeneca PLC: Revenue (by Region), 2015-2017
Figure 9.31    AstraZeneca PLC: R&D Expense, 2015-2017
Figure 9.32    AstraZeneca PLC: Global Presence
Figure 9.33    AstraZeneca PLC: SWOT Analysis
Figure 9.34    CELGENE CORPORATION: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.35    CELGENE CORPORATION: Overall Financials, 2015-2017
Figure 9.36    CELGENE CORPORATION: Revenue (by Region), 2015-2017
Figure 9.37    CELGENE CORPORATION: R&D Expense, 2015-2017
Figure 9.38    CELGENE CORPORATION: Revenue Forecast, 2015-2020
Figure 9.39    CELGENE CORPORATION: Global Presence
Figure 9.40    CELGENE CORPORATION: SWOT Analysis
Figure 9.41    Gilead Sciences, Inc: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.42    Gilead Sciences, Inc: Overall Financials, 2015-2017
Figure 9.43    Gilead Sciences, Inc: Revenue (by Region), 2015-2017
Figure 9.44    Gilead Sciences, Inc: R&D Expense, 2015-2017
Figure 9.45    Gilead Sciences, Inc: Revenue Forecast, 2015-2020
Figure 9.46    Gilead Sciences, Inc: Global Presence
Figure 9.47    Gilead Sciences, Inc: SWOT Analysis
Figure 9.48    Johnson & Johnson: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.49    Johnson & Johnson: Overall Financials, 2015-2017
Figure 9.50    Johnson & Johnson: Revenue (by Business Segment), 2015-2017
Figure 9.51    Johnson & Johnson: Revenue (by Region), 2015-2017
Figure 9.52    Johnson & Johnson: R&D Expense, 2015-2017
Figure 9.53    Johnson & Johnson: Revenue Forecast, 2015-2020
Figure 9.54    Johnson & Johnson: Global Presence
Figure 9.55    Johnson & Johnson: SWOT Analysis
Figure 9.56    Merck & Co., Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.57    Merck & Co., Inc.: Overall Financials, 2015-2017
Figure 9.58    Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
Figure 9.59    Merck & Co., Inc.: Revenue (by Region), 2015-2017
Figure 9.60    Merck & Co., Inc.: R&D Expense, 2015-2017
Figure 9.61    Merck & Co., Inc.: Revenue Forecast, 2015-2020
Figure 9.62    Merck & Co., Inc.: Global Presence
Figure 9.63    Merck & Co., Inc.: SWOT Analysis
Figure 9.64    Novartis AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.65    Novartis AG: Overall Financials, 2015-2017
Figure 9.66    Novartis AG: Revenue (by Business Segment), 2015-2017
Figure 9.67    Novartis AG: Revenue (by Region), 2015-2017
Figure 9.68    Novartis AG: R&D Expense, 2015-2017
Figure 9.69    Novartis AG: Revenue Forecast, 2015-2020
Figure 9.70    Novartis AG: Global Presence
Figure 9.71    Novartis AG: SWOT Analysis
Figure 9.72    Pfizer, Inc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.73    Pfizer, Inc.: Overall Financials, 2015-2017
Figure 9.74    Pfizer, Inc.: Revenue (by Business Segment), 2015, 2016 and 2017
Figure 9.75    Pfizer, Inc.: Revenue (by Region), 2015, 2016 and 2017
Figure 9.76    Pfizer, Inc.: R&D Expense, 2015-2017
Figure 9.77    Pfizer, Inc.: Revenue Forecast, 2015-2020
Figure 9.78    Pfizer, Inc.: Global Presence
Figure 9.79    Pfizer, Inc.: SWOT Analysis
Figure 9.80    F. Hoffmann-La Roche AG: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.81    F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure 9.82    F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure 9.83    F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure 9.84    F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure 9.85    F. Hoffmann-La Roche AG: Revenue Forecast, 2015-2020
Figure 9.86    F. Hoffmann-La Roche AG: Global Presence
Figure 9.87    F. Hoffmann-La Roche AG: SWOT Analysis
Figure 9.88    Sanofi S.A.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.89    Sanofi S.A: Overall Financials, 2015-2017
Figure 9.90    Sanofi S.A: Revenue (by Business Segment), 2015-2017
Figure 9.91    Sanofi S.A: Revenue (by Region), 2015-2017
Figure 9.92    Sanofi S.A: R&D Expense, 2015-2017
Figure 9.93    Sanofi S.A: Revenue Forecast, 2015-2020
Figure 9.94    Sanofi S.A: Global Presence
Figure 9.95    Sanofi S.A: SWOT Analysis
Figure 9.96    Shire plc.: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.97    Shire plc.: Overall Financials, 2015-2017
Figure 9.98    Shire PLC: Revenue (by Business Segment), 2015-2017
Figure 9.99    Shire PLC: R&D Expense, 2015-2017
Figure 9.100    Shire PLC: Revenue Forecast, 2015-2020
Figure 9.101    Shire PLC: Global Presence
Figure 9.102    Shire PLC: SWOT Analysis
Figure 9.103    Teva Pharmaceuticals Industries Limited: Product Offerings for Global Nanopharmaceutical Drugs Market
Figure 9.104    Teva Pharmaceuticals Industries Limited: Overall Financials, 2015-2017
Figure 9.105    Teva Pharmaceuticals Industries Limited: Revenue (by Business Segment), 2015-2017
Figure 9.106    Teva Pharmaceuticals Industries Limited: Revenue (by Region), 2015-2017
Figure 9.107    Teva Pharmaceuticals Industries Limited: R&D Expense, 2015-2017
Figure 9.108    Teva Pharmaceuticals Industries Limited: Revenue Forecast, 2015-2020
Figure 9.109    Teva Pharmaceuticals Industries Limited: Global Presence
Figure 9.110    Teva Pharmaceuticals Industries Limited: SWOT Analysis
Figure 10.1    Global Nanopharmaceutical Drugs Market Scope
Figure 10.2    Global Nanopharmaceutical Drugs Market: Research Methodology
Figure 10.3    Primary Research
Figure 10.4    Secondary Research
Figure 10.5    Data Triangulation
Figure 10.6    Top-down Approach (Segment-wise Analysis)
Figure 10.7    Bottom-up Approach (Segment-wise Analysis)
Figure 10.8    Assumptions and Limitations
Figure 10.9    Considered Factors for Data Prediction and Modelling

Big pharma companies rely on blockbuster drugs for revenue generation. The patent protection allows the pharma company to sell the drugs at high profit margin, for example the Pfizer’s drug known as Lipitor, accounts for about $13 bn of Pfizer's revenues. Many blockbuster drugs are going off patent, drug manufacturers are facing challenges to develop novel research and development strategies, involving miniaturization through various techniques including nanotechnology.

The introduction of nanotechnology in medicines has revolutionized the pharmaceutical industry. With the advancement in the Nano pharmaceutical industry, the number of patent filings has dramatically increased. Pharmaceutical companies have developed new strategies & techniques to re-patent drugs which are on the way to expiration by modifying them with the help of nanotechnology. Nanodrugs offers a promising potential in terms of revenue growth.

The nanopharmaceuticals have broach range of application and are used in imaging, diagnostics and therapeutics and possess full potential to dominate the pharmaceutical market. The introduction of nanomedicine will alter the landscape of medicine and will drastically improve a patient's quality of life and reduce healthcare costs.

The purpose of this study is to gain a holistic view of the nanopharmaceutical drugs market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the drugs associated with the global nanopharmaceutical drugs market across different regions. The market has been segmented into ‘drug carrier type,’ ‘application,’ ‘distribution channel,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market. The global nanopharmaceutical drug market is valued $40.37 billion in 2017 and is expected to reach $79.29 billion by 2026.

The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. are the key drivers for the growth of the nanopharmaceutical drugs market.

Moreover, among different therapeutic areas, the oncology therapeutic area  dominated the global nanopharmaceutical drugs market in 2017. Nanoparticles offer an opportunity to introduce overall shift in cancer research. Many drug candidates are under clinical investigation and have the potential to be introduced in the market. Ideal nanomedicines should follow the regulatory pathway of approval and should have a modular design that can be easily scaled up for cGMP manufacturing and stored for a long time prior to use in patients. The Nanotechnology Characterization Laboratory and FDA works in collaboration to advance and review nanomedicine platform.

On the basis of regions, the global nanopharmaceutical drugs market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global nanopharmaceutical drugs market and contributed 51.78% in terms of revenue respectively to the global market in 2017. However, Europe and Asia-Pacific is expected to grow at a significant CAGR  between 5% to 7% in terms of revenue respectively, during the forecast period.

The key players who have been contributing significantly to the nanopharmaceutical drugs market include Pfizer, Inc, AstraZeneca, Gilead Sciences, and Astellas Pharma Inc., Abbvie Inc., Amgen, Merck & Co., Inc., Hoffmann-La Roche AG., Teva Pharmaceuticals Industries Limited, Novartis AG, CELGENE CORPORATION, Sanofi S.A., JOHNSON & JOHNSON, AMAG Pharmaceuticals and Shire plc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields


related reports



Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors